New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
17:46 EDTANTHAnthera Pharmaceuticals reports Q2 EPS (34c), consensus (49c)
As of June 30, the company's cash, cash equivalents and restricted cash was $22.8M, compared to $35.9M at December 31, 2013.
News For ANTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
06:03 EDTANTHAnthera price target raised to $7.50 from $5 at Piper Jaffray
Piper Jaffray raised its price target for shares of Anthera Pharmaceuticals to $7.50 saying the company's strengthened balance sheet is enough to fund its Phase III trials. It reiterates an Overweight rating on the stock.
March 19, 2015
15:02 EDTANTHAnthera gets $3M research award from Cystic Fibrosis Foundation
Anthera Pharmaceuticals announced it has received an award from Cystic Fibrosis Foundation Therapeutic of up to $3M to support the manufacturing and clinical development of Anthera's novel pancreatic enzyme replacement therapy, Sollpura-liprotamase. Cystic Fibrosis Foundation Therapeutics is a non-profit affiliate of the Cystic Fibrosis Foundation.
March 18, 2015
09:23 EDTANTHOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTANTHAnthera Pharmaceuticals 5.5M share Spot Secondary priced at $4.50
Subscribe for More Information
March 17, 2015
19:42 EDTANTHOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTANTHAnthera Pharmaceuticals files to sell common stock, no amount given
Subscribe for More Information
March 16, 2015
08:45 EDTANTHAnthera Pharmaceuticals completes interim analysis from trial with Blisibimod
Anthera Pharmaceuticals, in collaboration with its partner Zenyaku Kogyo, announced that the BRIGHT-SC study of blisibimod in patients with IgA nephropathy should continue to completion as planned. This follows the successful completion of an interim futility analysis, conducted by an independent statistician, which evaluated several important biomarkers of renal disease in patients who had completed at least 8 weeks of treatment. As previously disclosed, following meetings with the European Medicines Agency, the Japanese PMDA, the US FDA, and our partner Zenyaku Kogyo, the company amended the BRIGHT-SC protocol prior to the interim analysis to reflect collective feedback. All agencies were receptive to the use of proteinuria as a surrogate endpoint with appropriate post-marketing studies.
08:22 EDTANTHAnthera Pharmaceuticals reports Q4 EPS (32c), consensus (33c)
08:14 EDTANTHAnthera Pharmaceuticals enters $10.3M purchase agreement
Anthera has filed a supplement for the sale of up to $10,300,000 in shares of our common stock to Lincoln Park Capital Fund, LLC, or Lincoln Park, under a Purchase Agreement entered into on March 12, 2015, or the Purchase Agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use